THALES
18.11.2020 07:02:05 CET | Business Wire | Press release
Damen Schelde Naval Shipbuilding and Thales signed on November 17, 2020, the contract for the delivery and full integration of Thales’s Mission and Combat System for the four MKS 180 class frigates contracted by the German Navy. The system will be designed by Damen and completely built by German shipyards, under Damen’s project management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005651/en/
Valued at €1.5B, the contract illustrates Thales’s leading position in naval global integration. It will be executed by Thales’s naval Centers of Excellence in Hengelo (the Netherlands), Kiel and Wilhelmshaven (Germany) in cooperation with a substantial number of German subcontractors.
Underpinning this contract is the proven cooperation of German and Dutch naval industries, including numerous joint opportunities for Damen and Thales in the Netherlands to innovate within naval shipbuilding projects, often with the participation of the Netherlands’ Ministry of Defence. The project underscores Damen’s and Thales’s ambition to build further cooperation with shipyards and partnering industries in high-end European naval programmes.
Thales’s Mission and Combat System includes the comprehensive Tacticos Combat Management System and the AWWS (Above Water Warfare System) Fire Control Cluster. The contract includes four ship systems, logistic services and multiple land-based test and training sites, as well as the option for one or two additional ships.
AWWS is a cutting-edge warfare suite that helps the ship crews to counter and neutralise complex saturation attacks by continuously analysing and optimising the tactical environment and deployment of resources. AWWS will be combined with APAR* Bl2, the evolved version of Thales’s proven AESA* multifunction radar. In 2019, Thales signed an AWWS development contract for the new M-frigates for the Belgian and Dutch Navies.
In the past years, Thales has been awarded several large contracts by European NATO navies, thanks to innovative solutions and its proven reliability as an industrial partner. These contracts have made Thales the de facto naval combat system partner of NATO.
The first ship of the MKS 180 class will be operational in 2028. The entire programme will run for over ten years.
“Winning such a substantial contract within the strict framework of an objective scoring system reinforces our global leading position in high-end naval integration. Thanks to our innovative capabilities, the German Navy will be able to execute both current and future tasks whilst substantially contributing to stability in the operational theatres all over the world.” Gerben Edelijn, CEO of Thales Netherlands.
“As a partner in the MKS 180 programme, Thales Deutschland not only contributes to a high German value-added share, but also brings many years of experience in European cooperation and proven systems expertise. This programme will create new, high-quality jobs in Germany, within an exemplary framework of European defence cooperation. We will also contribute to maintaining the German Navy's operational capability at the highest level within the alliance,” Dr. Christoph Hoppe, CEO of Thales Deutschland.
“We are very honoured by this notification which further solidifies our long-standing cooperation with the German Navy and Damen. We sincerely thank our customers for their continued trust. This huge contract anchors our position as global leader in high-end naval systems integration. The German Navy will benefit from cutting-edge technological systems thanks to the diversity of talents at Thales”. Patrice Caine, Chairman and CEO of Thales.
* APAR: Active Phased Array Radar
* AESA: Active Electronically Scanned Array
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
Thales in the naval domain
With more than 50 years of experience as a provider of naval equipment, systems and services, Thales offers naval forces around the world unrivalled expertise and proven operational benefits. Thales understands how naval and maritime affairs are evolving today, and leverages those insights to help ensure the success of a broad range of naval missions around the world. Thales air defence, surface defence, anti-submarine warfare and maritime safety & security systems are now in service with more than 50 navies.
Thales in the Netherlands
In the Netherlands, Thales employs about 2.200 staff members in Hengelo, Enschede, Huizen, Delft, The Hague and Eindhoven. They are contributing to the development, production and integration of complex systems for defence, transport and security. such as Command & Control, public transport chipcard, communication systems and cyber security.
Thales in Germany
Thales Deutschland is one of the largest national subsidiaries of the Thales group and employs 3,800 persons at 11 locations and carries out its own manufacturing and development. In 2019, Thales Deutschland generated sales of EUR 1.2 billion, predominantly German value added. Thales Deutschland, an integrated German electronics corporation and systems house, is a model of German engineering tradition. As a recognized member of Germany's high-tech industry, Thales Deutschland offers its customers at home and abroad state-of-the-art, highly secure and ultra-reliable communications, information and control systems, as well as services for secure ground, air and sea transportation, for both civilian and military security and protection needs. In addition, Thales Deutschland has a comprehensive portfolio of IT solutions for cyber security.
PLEASE VISIT
Thales Group
Market page
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom